April 28, 2020
A new FDA Fast Track designation for Zambon
The designation is for L‑CsA‑i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company. MILAN–(BUSINESS…
Pharmaceuticals, Biotechnology and Life Sciences
The designation is for L‑CsA‑i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company. MILAN–(BUSINESS…